Strategy

In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding a suite of clinical-stage immunology assets to its portfolio, Insilico Medicine enters an AI-powered drug discovery collaboration with SK Biopharmaceuticals valued at up to $2.5 billion to advance neuroimmune treatments in the central nervous system, and Pharmaceutical Executive speaks with Kyle Smith, president and COO of Aprecia Pharmaceuticals, on the real-world benefits and persistent challenges of operating as a fully domestic manufacturer in an era of tariffs and supply chain pressure.

The acquisition will bolster AbbVie’s pipeline, including the addition of monoclonal antibody treatment zumilokibart.

Marketers must navigate a new landscape that sees customers expecting highly-personalized experiences that mirror their experiences with non-health brands.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

Model N Senior Vice President Jesse Mendelsohn explores the hidden costs and realities of PBM-driven drug pricing and the growing challenges manufacturers face in ensuring contract compliance, formulary access and reimbursement accuracy.

Between 2026 and 2030, billions of dollars in revenue will be at risk due to expiring patents and periods of exclusivity.

The Deloitte Consulting partner discusses how GLP-1s are becoming key value drivers and driving R&D focus during a period of market concentration.

The takeaway leadership message from our May issue is clear: Future progress will come from those willing to rethink the machinery — not just the medicine.

BeOne Medicines’ John Oyler on building an oncology pharma power from a disruptive idea — and playing the long game on speed, science and scale.

Aradigm Health’s CEO discusses how payers and other entities in the healthcare ecosystem are developing strategies to ensure cell & gene therapy costs don’t prevent patients from accessing them.

Why biopharma's targeting model is overdue for evolution.

Innomar’s VP of commercial strategy and innovation discusses the shifting global landscape and building relationships with pharma manufacturers.

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single adaptive engine.

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.

Pfizer’s broad pipeline and recent acquisitions have yet to translate into a coherent market narrative, contributing to investor uncertainty during a critical period of strategic transition.

Model N’s Michael Grosberg breaks down the accelerated complexity, policy disruption, and data gaps testing manufacturer market access and revenue management strategies.

Thomas Newcomer of Samsung Bioepis discusses how certain classes of drugs don’t have enough biosimilars in development and the impact that this can have in the coming years.

Ken Banta and Andy Milligan explore how life sciences leaders can rebuild relevance, consistency, and trust in today's complex and cost-focused era of healthcare.

New studies from 23andMe suggest genetic variation may modestly influence GLP-1 weight-loss response and side effects.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.

Analysis of U.S. drug pricing reform in 2026 highlights how the Inflation Reduction Act, Medicare drug price negotiation, and most-favored-nation pricing initiatives are reshaping pharmaceutical pricing, limiting patent-driven market exclusivity, accelerating generic and biosimilar competition, and driving strategic shifts in market access, pricing models, and innovation priorities across the biopharma industry.

In Part 2 of our podcast video episode with ZS CEO Pratap Khedkar, he breaks down pharma's need to move beyond AI pilots to scalable impact—and how companies can "go from informing to solving" while navigating trust, regulation, and a rapidly shifting patient dynamic.